Search

Your search keyword '"Palumbo, Antonio"' showing total 2,519 results

Search Constraints

Start Over You searched for: Author "Palumbo, Antonio" Remove constraint Author: "Palumbo, Antonio"
2,519 results on '"Palumbo, Antonio"'

Search Results

1. The extracellular matrix protein EMILIN-1 impacts on the microenvironment by hampering gastric cancer development and progression

2. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.

3. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life

5. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

6. Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real‐world evidence.

7. Antioxidant capacity, antitumor activity and metabolomic profile of tamarillo (Solanum betaceum).

14. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

16. Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials

17. Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis

18. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

19. Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response

21. PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling

23. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

26. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma

27. Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial

30. Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis

31. Supplementary Figure 4 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

32. Supplementary Figure 4 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

33. Supplementary Figure 3 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

35. Supplementary Table 2 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

36. Supplementary Figure 2 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

37. Supplementary Figure 1 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

38. Supplementary Table 3 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

39. Supplementary Table 1 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

40. Supplementary Table 2 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

41. Supplementary Table 1 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

42. Supplementary Methods from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

43. Supplementary Figure 1 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

44. Supplementary Figure 5 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

45. Supplementary Figure 2 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

46. Supplementary Figure 3 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

48. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

49. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma

50. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Catalog

Books, media, physical & digital resources